Antimicrobial resistance (AMR) is one of the most urgent threats to modern medicine, making infections harder to treat and increasing risk, cost, and mortality. Advancing AMR research—especially through rapid diagnostics—is essential to protecting patients and preserving the effectiveness of existing therapies.
Antimicrobial resistance (AMR) is one of the most urgent threats to modern medicine, making infections harder to treat and increasing risk, cost, and mortality. Advancing AMR research—especially through rapid diagnostics—is essential to protecting patients and preserving the effectiveness of existing therapies.
Traditional diagnostics can take days, often leading to broad-spectrum antibiotic use. *Rapid diagnostic technologies* enable faster pathogen identification and resistance detection, supporting timely, targeted treatment and stronger antimicrobial stewardship.
* Earlier, more precise therapy
* Reduced unnecessary antibiotic use
* Improved clinical outcomes
* Slower spread of resistance
Traditional diagnostics can take days, often leading to broad-spectrum antibiotic use. *Rapid diagnostic technologies* enable faster pathogen identification and resistance detection, supporting timely, targeted treatment and stronger antimicrobial stewardship.
* Diagnostic accuracy and utility studies
* Resistance profiling and surveillance
* Stewardship and outcomes research
* Pragmatic and observational trials across real-world settings
AMR and diagnostics studies are well-suited for hospitals, infectious disease practices, urgent care centers, and laboratories.
Sites benefit from lower patient burden and faster study timelines, while sponsors gain access to scalable, real-world environments that reflect everyday clinical practice.